| Filed On | Filing |
|---|---|
| 13 Nov 2026 | SCHEDULE 13G/A |
| 09 Nov 2026 | 10-Q |
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
GAITHERSBURG, Md., November 9, 2026 — GeneDx Holdings Corp. (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today reported its financial results for the third quarter of 2026. |
| 06 Nov 2026 | SCHEDULE 13G |
| 18 Sep 2026 |
Form 4: Stueland Katherine, Director
Received 18,750 shares by exercise or conversion · Sold 10,501 shares ($1.03M) |
| 18 Sep 2026 |
Form 4: Feeley Kevin, CHIEF FINANCIAL OFFICER
Received 7,197 shares by exercise or conversion · Sold 3,728 shares ($364K) |
| 18 Sep 2026 |
Form 4: Fuchs Thomas, Director
Received 1,146 shares by exercise or conversion |
| 11 Sep 2026 |
Form 4: Stueland Katherine, Director
Received 6,547 shares by exercise or conversion · Sold 3,692 shares ($311K) |
| 11 Sep 2026 |
Form 4: Feeley Kevin, CHIEF FINANCIAL OFFICER
Received 2,462 shares by exercise or conversion · Sold 1,285 shares ($108K) |
| 03 Sep 2026 |
Form 4: Feeley Kevin, CHIEF FINANCIAL OFFICER
Received 717 shares by exercise or conversion · Sold 372 shares ($31.2K) |
| 01 Sep 2026 | 144 |
| 01 Sep 2026 | 144 |
| 11 Aug 2026 | SCHEDULE 13G |
| 07 Aug 2026 | SCHEDULE 13G/A |
| 03 Aug 2026 | 10-Q |
| 03 Aug 2026 |
8-K: Results of Operations and Financial Condition
GAITHERSBURG, Md., August 3, 2026 — GeneDx Holdings Corp. (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today reported its financial results for the second quarter of 2026. |
| 28 Jul 2026 | SCHEDULE 13G |
| 21 Jul 2026 | 25-NSE |
| 01 Jul 2026 |
Form 4: Gardner Mark A, President
Granted 35,441 Restricted Stock Unit |
| 23 Jun 2026 |
Form 4: Ryan Jason, Director
Received 3,576 shares by exercise or conversion |
Loading...